Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

Frank Stephen Hodi, Vanna Chiarion‐Sileni, Rene C. Gonzalez et al. · The Lancet Oncology · 2018

Cited by 1,395 works. doi:10.1016/s1470-2045(18)30700-9

Authors

References